195314-47-7

Upstream product

• 13057-17-5 bromethyl methyl ether 
• 17332-11-5 2-bromo-4-methoxyphenol 
• 150-76-5 4-methoxy-phenol 
• 107-30-2 chloromethyl methyl ether 

Downstream Products

• 1444004-64-1 [carboxy-¹⁴C]ethyl 2-hydroxy-5-methoxy-benzoate 
• 1444004-65-2 ethyl 2-(2-ethoxy-2-oxo-ethoxy)-5-methoxy(carboxy-¹⁴C)benzoate 
• 1444004-66-3 2-(carboxymethyloxy)-5-methoxy-(carboxy-¹⁴C)benzoic acid 
• 1444004-63-0 [carboxy-¹⁴C]5-methoxy-2-(methoxymethoxy)benzoic acid 
• 7414-92-8 Tetrangulol 
• 937591-48-5 4-methoxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol 

Relevant academic research and scientific papers

P-Stereogenic Phosphonates via Dynamic Kinetic Resolution: A Route towards Enantiopure Tertiary Phosphine Oxides

Asymmetric synthesis of P-stereogenic phosphonates presents a great challenge. Following this target we disclose herein a DKR strategy towards the O–P coupling reaction between an easily accessible enantiopure phenol bearing a chiral sulfinyl auxiliary an

A study of enantioselective syntheses by Sharpless asymmetric oxidation for aryl sulfoxides containing oxygen groups at the ortho position

Abstract: While ortho-alkoxy aryl sulfoxides including various substituents were synthesized by Sharpless asymmetric oxidation reaction, we optimized the reaction conditions and screened better combination of starting materials to obtain high enantioselectivity. The result suggested new information that electron-withdrawing substituents on the aromatic ring have a strong influence upon enantioselectivity of the products. Also, several chiral ligands for Sharpless asymmetric oxidation reaction were evaluated to improve the enantioselectivity. Graphic abstract: High enantioselectivity of ortho-alkoxy aryl chiral sulfoxides have been achieved by Sharpless oxidation reaction using Ti(O-i-Pr)4 and diethyl tartrate under anhydrous condition. In particular, the enantioselctivity of products was influenced by electron-withdrawing substituents on the aromatic ring, such as nitro, ester and aldehyde groups.[Figure not available: see fulltext.]

Rhodium(II)-Catalyzed Aryl C?H Carboxylation of 2-Pyridylphenols with CO2

A protocol for C?H carboxylation of electron-deficient 2-pyridylphenols with CO2 through a Rh(II)-catalyzed C?H bond activation under redox-neutral conditions has been developed. A suitable phosphine ligand was crucial for this reaction. This m

A concise approach to tetracyclic spiroamine scaffold of erythrinan alkaloids via an oxidative dearomatization-spirocyclization sequence

This paper describes a novel synthetic approach to 11,12-dimethoxy-8,9-dihydro-1H-indolo[7a,1-a]isoquinoline-2,6-dione, which is a key synthetic intermediate to some erythrinan alkaloids. This concise approach features an oxidative dearomatization-spirocy

Carbon-14 radiosynthesis of the benzofuran derivative and β-amyloid plaque neuroimaging positron emission tomography radioligand AZD4694

In support of a metabolite study, the β-amyloid plaque neuroimaging positron-emission tomography radioligand AZD4694 was labeled with carbon-14 in 10 radiosynthetic steps starting from radiolabeled carbon dioxide. [ 14C]AZD4694 was labeled in t

Phenoxy thiazole derivatives as potent and selective acetyl-CoA carboxylase 2 inhibitors: Modulation of isozyme selectivity by incorporation of phenyl ring substituents

A phenyl ring substitution strategy was employed to optimize the ACC2 potency and selectivity profiles of a recently discovered phenoxy thiazolyl series of acetyl-CoA carboxylase inhibitors. Ring substituents were shown to dramatically affect isozyme sele

Palladium-catalyzed couplings to nucleophilic heteroarenes: The total synthesis of (-)-frondosin B

The total synthesis of (-)-frondosin B, the enantiomer of naturally-occuring (+)-frondosin B, is described, wherein a palladium-catalyzed cyclization is used to establish the tetracyclic ring system of the natural product. Graphical Abstract.

Phenol compound having antioxidative activity and the process for preparing the same

Disclosed are a phenol compound represented by the formula (1): STR1 wherein R0 represents H, alkyl or alkyloxy; R1 represents alkyl; R2 represents alkyl or alkyloxy; OR3 represents OH; R4 represents H, lower alkyl or acyl, each of the above substituents may be substituted; W represents O, S or NR7 ; where R7 represents H, alkyl, aryl, OH or alkyloxy, a group of the formula (2): STR2 represents an amino which may be mono- or di-substituted or heterocyclic group containing N atom, or a pharmaceutically acceptable salt thereof, and a process for preparing the same.